Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s
Video

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Launching: Thursday 24th April 2025
 
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in:

25-04-2024 | Bariatric Surgery | Original Contributions

The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease

Authors: Ali Esparham, Saeed Shoar, Ali Mehri, Zhamak Khorgami, Venkat R. Modukuru

Published in: Obesity Surgery | Issue 7/2024

Login to get access

Abstract

Purpose

There is a strong association between metabolic dysfunction–associated steatotic liver disease (MASLD) and obesity which are both important risk factors for cardiovascular diseases (CVDs). The current study aimed to assess the association of MBS with different CVDs in patients with MASLD.

Materials and Methods

The National Inpatient Sample (NIS) database from 2016 to 2020 were analyzed by using ICD-10 codes. A propensity score matching in a 1:1 ratio was done to match the MBS and non-MBS groups.

Results

After weighted analysis, 1,124,155 and 68,215 patients were included in non-MBS and MBS groups, respectively. MBS was associated with significantly lower risk of hospitalization for coronary artery disease (OR 0.633 (0.569–0.703), p value < 0.001), acute myocardial infarction (OR 0.606 (0.523–0.701), p value < 0.001), percutaneous coronary intervention (OR 0.578 (0.489–0.682), p value < 0.001), and thrombolysis (OR 0.765 (0.589–0.993), p value = 0.044) compared to the non-MBS group in patients with MASLD. Furthermore, MBS was associated with 52% reduced risk of hospitalization for hemorrhagic stroke in patients with MASLD (OR 0.481, 95% CI 0.337–0.686, p value < 0.001). However, ischemic stroke was not significant between the two groups (OR 1.108 (0.905–1.356), p value = 0.322). In addition, MBS was associated with 63% and 60% reduced risk of hospitalization for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients with MASLD (OR 0.373, 95% CI 0.300–0.465 and OR 0.405, 95% CI 0.325–0.504, p value < 0.001 for both), respectively.

Conclusion

The current study showed that MBS is significantly associated with a reduced risk of hospitalization for CVD in patients with MASLD.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
2.
Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.CrossRefPubMed
3.
Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.CrossRefPubMedPubMedCentral
4.
Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.CrossRefPubMed
5.
Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100(5–6):481–99.CrossRefPubMed
6.
7.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.CrossRefPubMed
8.
Chen B, Tang WHW, Rodriguez M, et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin Liver Dis. 2022;42(4):465–74.CrossRefPubMed
9.
Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85.CrossRefPubMed
10.
Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215.CrossRefPubMed
11.
Chan WK, Chuah KH, Rajaram RB, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213.CrossRefPubMedPubMedCentral
12.
van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955–69.CrossRefPubMedPubMedCentral
13.
Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRefPubMed
14.
Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528–62.CrossRefPubMed
15.
Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42.CrossRefPubMedPubMedCentral
16.
Elsaid MI, Li Y, Bridges JFP, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open. 2022;5(10):e2235003.CrossRefPubMedPubMedCentral
17.
Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw Open. 2023;6(4):e237188.CrossRefPubMedPubMedCentral
18.
Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Network Open. 2020;3(4):e201997-e.CrossRef
19.
Minhas AMK, Bhopalwala HM, Dewaswala N, et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Current Problems Cardiol. 2022;48:101199.CrossRef
20.
21.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.CrossRefPubMed
22.
Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018;22(1):133–40.CrossRefPubMed
23.
Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97(13):e0214.CrossRefPubMedPubMedCentral
24.
Elsaid MI, Bridges JF, Li N, et al. Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro Hep Advances. 2022;1(3):445–56.CrossRef
25.
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.CrossRefPubMed
26.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.CrossRefPubMed
27.
Lazarus JV, Mark HE, Colombo M, et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022;55(2):234–43.CrossRefPubMed
28.
Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):339–50.CrossRefPubMed
29.
Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66.CrossRefPubMed
30.
Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.CrossRefPubMed
31.
Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMed
32.
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.CrossRefPubMed
33.
Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterol. 2020;159(4):1290-301.e5.CrossRef
34.
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.CrossRefPubMed
35.
Oliveras A, Molina L, Goday A, et al. Effect of bariatric surgery on cardiac structure and function in obese patients: role of the renin-angiotensin system. The Journal of Clinical Hypertension. 2021;23(1):181–92.CrossRefPubMed
36.
Villarreal-Calderón JR, Cuéllar RX, Ramos-González MR, et al. Interplay between the adaptive immune system and insulin resistance in weight loss induced by bariatric surgery. Oxid Med Cell Longev. 2019;2019:3940739.CrossRefPubMedPubMedCentral
37.
Seyyedi J, Alizadeh S. Effect of surgically induced weight loss on biomarkers of endothelial dysfunction: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3549–60.CrossRefPubMed
38.
Esparham A, Shoar S, Kheradmand HR, et al. The impact of bariatric surgery on cardiac structure, and systolic and diastolic function in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2023;33(1):345–61.CrossRefPubMed
39.
Esparham A, Roohi S, Ahmadyar S, Dalili A, Nelson P, Khorgami Z. Impact of bariatric surgery on carotid intima-media thickness, flow-mediated dilation, and nitrite-mediated dilation: a systematic review and meta-analysis. Surg Obesity Related Diseases. 2023;19:1188.CrossRef
Metadata
Title
The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease
Authors
Ali Esparham
Saeed Shoar
Ali Mehri
Zhamak Khorgami
Venkat R. Modukuru
Publication date
25-04-2024
Publisher
Springer US
Published in
Obesity Surgery / Issue 7/2024
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-024-07238-w

Other articles of this Issue 7/2024

From Bands to Bypasses: Navigating Safety of Band Conversions to Roux-en-Y Gastric Bypass and Single Anastomosis Duodenoileostomy Versus Sleeve Gastrectomy

Laparoscopic Conversion of Gastric Plication to One Anastomosis Gastric Bypass

  • Open Access
  • Obesity
  • Multimedia Article

The Impact of Bariatric Surgery on Nitrogen Balance at Six months Post-surgery

Remnant Gastrectomy and Gastric Bypass: A Systematic Review of Indications and Outcomes of Resectional Gastric Bypass

Effect of Sleeve Gastric Surgery on Body Weight and Hypothalamic-Pituitary Axis Hormone Levels in Patients with Polycystic Ovary Syndrome

More Long-Term Evidence for the Efficiency of LSG Versus LRYGB for T2DM Remission in Patients with Obesity Is Needed

  • Obesity
  • Letter to Editor/LED Reply
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Video
Image Credits